Sonesitatug vedotin has revealed direct killing effects on CLDN18.2-overexpressing cancer cells via MMAE-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) as well as indirect killing effects on bystander cancer cells through MMAE release from sonesitatug vedotin-internalized cells, which results in antitumor activities in preclinical models of gastric and pancreatic cancers (Xu G. et al., 2024). This evidence concerns the gene CLDN18 and pancreatic neoplasm.